Current and emerging maintenance therapies for ulcerative colitis

被引：4
作者：
O'Connor, Anthony [1 ]
Moss, Alan C. [1 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA 02215 USA
来源：
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | 2014年 / 8卷 / 04期
关键词：
thiopurines; adalimumab; maintenance; remission; infliximab; 5-ASA; golimumab; ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; LONG-TERM MAINTENANCE; 5-AMINOSALICYLIC ACID MESALAZINE; COLORECTAL NEOPLASIA; DOUBLE-BLIND; RISK-FACTOR; THIOPURINE METHYLTRANSFERASE; INFLIXIMAB MAINTENANCE; RANDOMIZED MULTICENTER; MAINTAINING REMISSION;
D O I：
10.1586/17474124.2014.896193
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ulcerative colitis (UC) is a chronic idiopathic intestinal disease that requires life-long maintenance therapy to maintain clinical remission. This article reviews the current literature on maintenance treatments in UC. It examines the natural history of the condition and the proposed benefits of treatment. These include improving quality of life parameters, decreasing corticosteroid intake, the prevention of relapse, the prevention of colorectal cancer and the avoidance of colectomy. The immunosuppressive era appears to be reducing the need for elective colectomy in UC. The article explores the classes of drug currently used for maintenance of UC, reviews the literature around adherence issues, and summarizes emerging agents in this space.
引用
收藏
页码：359 / 368
页数：10
相关论文
共 90 条
[1]  
ADLER DJ, 1990, AM J GASTROENTEROL, V85, P717
[2]   Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis [J].
Ardizzone, S ;
Maconi, G ;
Russo, A ;
Imbesi, V ;
Colombo, E ;
Porro, GB .
GUT, 2006, 55 (01) :47-53
[3]  
Brereton Nic, 2010, J Med Econ, V13, P148, DOI 10.3111/13696990903562861
[4]   The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis [J].
Buckland, A. ;
Bodger, K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (11-12) :1287-1296
[5]  
Carter CT, 2011, AM J MANAG CARE, V17, P385
[6]  
Cohen RD, 2000, AM J GASTROENTEROL, V95, P1263
[7]   Epidemiology and Natural History of Inflammatory Bowel Diseases [J].
Cosnes, Jacques ;
Gower-Rousseau, Corinne ;
Seksik, Philippe ;
Cortot, Antoine .
GASTROENTEROLOGY, 2011, 140 (06) :1785-U118
[8]   Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab [J].
Croft, A. ;
Walsh, A. ;
Doecke, J. ;
Cooley, R. ;
Howlett, M. ;
Radford-Smith, G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (03) :294-302
[9]   Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis [J].
D'Haens, Geert ;
Sandborn, William J. ;
Barrett, Karen ;
Hodgson, Ian ;
Streck, Paul .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (07) :1064-1077
[10]  
dAlbasio G, 1997, AM J GASTROENTEROL, V92, P1143
123456789